ATP citrate lyase Inhibitors
1 drugsAbout ATP citrate lyase
ATP-citrate lyase (ACLY) catalyzes the conversion of citrate and CoA to oxaloacetate and acetyl-CoA, a key building block for fatty acid and cholesterol synthesis. The enzyme plays a crucial role in lipid metabolism within the cytoplasm.
ACLY is a drug target in the metabolic therapeutic area due to its involvement in lipid production. Currently, there is no genetic evidence directly linking ACLY to specific diseases, but its role in lipid metabolism makes it a compelling target.
ACLY is targeted by two FDA-approved small molecule drugs, NEXLIZET and NEXLETOL, both from ESPERION THERAPS INC. These drugs highlight the potential of ACLY inhibition for therapeutic benefit in metabolic indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Coronary Atherosclerosis with only 1 trials.
Top ATP citrate lyase Drugs
ESPERION THERAPS INC is the only company with approved drugs targeting ACLY.
High market concentration suggests significant entry barriers or limited commercial interest.
ATP citrate lyase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ATP citrate lyase, using small molecule modality.
Explore alternative modalities like antibodies to differentiate from existing therapies.
ATP citrate lyase Clinical Trials 32 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 0 | 2 | 100% |
| Phase 3 | 14 | 9 | 0 | 5 | 100% |
| Phase 4 | 4 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ATP citrate lyase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ATP citrate lyase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
ATP citrate lyase Drug Approval Timeline (2020 - 2020)
The first drug targeting ACLY was approved in 2020, with the most recent approval also in 2020.
Recent approvals indicate a renewed interest, but saturation may occur quickly.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 39 clinical trials targeting ATP citrate lyase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities